Progressing a Phase I Trial of FAP-Exd (AVA6103), a Fibroblast Activation Protein (FAP)- Enabled Peptide-Drug Conjugate Delivering Sustained Tumour Microenvironment Release of Exatecan in Patients with FAP-Positive Solid Tumours
11:30 am - Monday 8th March 2027
- Leveraging peptide-drug conjugate designs to selectively release potent cytotoxic payloads within the tumour microenvironment through FAPmediated linker cleavage to maximise tumour exposure while minimising systemic toxicity
- Advancing AVA6103 (FAP-activated exatecan; FAPExd), through Phase 1a dose escalation, with Phase 1b expansion anticipated to commence in 2027
- Highlighting emerging data into target engagement, mechanism of action and the potential of FAPenabled tumour-selective drug delivery in several solid-tumour types